A randomized, masked, cross-over trial of XXXX for inflammatory @entity1103 .

@entity1 @entity644 @entity227 @entity1289 @entity1103 @entity3193 @entity3593 @entity551 @entity4816
PURPOSE: To analyze the effect of @entity1289 ( @entity1289 ) inhibitor @entity3593 on @entity1103 and @entity227 . DESIGN: Randomized, double-blind, placebo-controlled cross-over trial. METHODS: setting: Outpatient clinic of the Department of Ophthalmology at the University Medical Center of Utrecht. @entity1 : Forty @entity1 with @entity1103 were included. intervention: Each @entity1 received @entity3593 (10 mg daily) or placebo for three months. After two months of a @entity3593 /placebo free wash-out period, the groups received the reverse study medication for three months. Fluorescein angiography was performed to evaluate the retina. main outcome measures: @entity1103 , @entity227 and contrast sensitivity. RESULTS: @entity3593 had no effect on @entity1103 , @entity227 , papillary leakage, @entity4816 , and @entity3193 . In a subgroup analysis, we observed a @entity551 ( @entity3593 , 14 of 36 @entity1 ; placebo, 5 of 36 @entity1 ; P = .02) and a decrease in morning @entity644 ( @entity3593 , 23 of 35 @entity1 ; placebo 10 of 34 @entity1 , P = .003) was observed. CONCLUSIONS: Although @entity3593 had no effect on @entity1103 and @entity227 , we found a positive effect on the vascular system.
